Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chisan (also known as ADAPT-232) is a standardized herbal combination product containing extracts of three adaptogenic plants: *Rhodiola rosea* (Arctic root), *Schisandra chinensis* (Schisandra berry), and *Eleutherococcus senticosus* (Siberian ginseng). Developed and marketed by Circius Pharma, it is used as an adaptogen to alleviate symptoms of fatigue, tiredness, and weakness, and to improve physical performance. The active components work synergistically to modulate the stress response and provide protective effects against physical and mental stressors. While primarily marketed as a traditional herbal medicine or dietary supplement for over-the-counter use, it has been investigated in clinical trials as an adjuvant therapy for acute non-specific pneumonia and Long COVID symptoms, showing potential benefits in improving quality of life and reducing recovery time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chisan.